The ABCC1 Knockout HCT 116 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal carcinoma HCT 116 cell line. This product provides a heterogeneous pool of cells carrying targeted disruptions in the ABCC1 gene, enabling loss-of-function studies without clonal selection artifacts. The polyclonal format retains genetic diversity while abolishing ABCC1 protein expression, offering a robust model for multidrug resistance research. These cells serve as a critical tool for investigating ATP-binding cassette transporter biology, drug efflux mechanisms, and the molecular determinants of chemotherapeutic resistance. As a genomically defined knockout resource, they support high-content screening, functional genomics, and targeted therapeutic discovery in oncology.
The parental HCT 116 cell line is a well-characterized epithelial model derived from a human colorectal carcinoma, exhibiting microsatellite instability and a near-diploid karyotype. Widely employed in colorectal cancer research, HCT 116 cells display rapid proliferation, morphological homogeneity, and high transfection efficiency, making them amenable to genetic manipulation. Their endogenous expression of ABC transporters, including ABCC1, contributes to baseline drug resistance phenotypes, providing a physiologically relevant background for evaluating transporter-mediated efflux. This cell line??s well-documented signaling pathways, including WNT/??-catenin and MAPK cascades, further facilitate mechanistic studies in a cancer-relevant context. The knockout cells thus preserve the parental line??s core characteristics while enabling precise dissection of ABCC1 function.
ABCC1 (multidrug resistance-associated protein 1, MRP1) is an ATP-dependent transmembrane transporter that mediates the cellular efflux of a broad spectrum of organic anions, primarily glutathione, glucuronide, and sulfate conjugates. Transcriptionally activated by NFE2L2 (NRF2) and YBX1, and modulated by TP53, NR1I2 (pregnane X receptor), and NR1I3 (constitutive androstane receptor), ABCC1 is a central node in xenobiotic defense. It actively transports leukotriene C4 (LTC4), glutathione disulfide, and estrogen glucuronides, while reducing intracellular accumulation of chemotherapeutics such as doxorubicin, vincristine, and methotrexate. ABCC1 functions in concert with other ABC family members, including ABCB1 (MDR1), ABCG2 (BCRP), ABCC2 (MRP2), and ABCC3 (MRP3), and cooperates with glutathione-S-transferase enzymes and glutathione synthesis regulators like GCLC and GCLM. Its activity is tightly coupled to cellular glutathione homeostasis and oxidative stress responses.
In the HCT 116 colorectal cancer background, ABCC1 knockout recapitulates a clinically relevant loss-of-function scenario, where the absence of this major efflux pump enhances sensitivity to a wide range of anticancer agents. This model enables investigators to delineate the contribution of ABCC1 to intrinsic and acquired drug resistance, independent of compensatory transporter upregulation. It provides an isogenic system for studying how NRF2-driven detoxification programs and p53 status influence transporter expression and function. Moreover, the polyclonal population mirrors the heterogeneity of tumor responses, offering a more realistic platform for testing therapeutic interventions than monoclonal derivatives. Researchers can use these cells to explore the interplay between ABCC1 and parallel resistance mechanisms, such as ABCG2-mediated efflux, and to assess the efficacy of dual ABC transporter inhibitors.
These polyclonal knockout cells are suitable for a range of quantitative pharmacological assays, including calcein-AM efflux measurements, doxorubicin accumulation analysis by flow cytometry, and cell viability readouts (MTS/MTT) to determine drug sensitivity profiles. They facilitate mechanistic studies through western blotting for transporter expression, RT-qPCR for transcriptional regulators, and functional complementation experiments with wild-type or mutant ABCC1 constructs. Applications extend to high-throughput screening of small-molecule inhibitors that selectively target ABCC1, pharmacokinetic profiling of novel compounds, and elucidation of signaling pathways that converge on multidrug resistance. The model also supports co-culture and tumor microenvironment studies to evaluate how drug penetration and resistance evolve in complex settings. For additional technical details or custom inquiries, please contact Ascent Research.
